• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    5/24/23 12:48:08 PM ET
    $A
    $ADI
    $AMBO
    $ANF
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Semiconductors
    Technology
    Get the next $A alert in real time by email

    Gainers

    • Minerva Surgical, Inc. (NASDAQ:UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.
    • EpicQuest Education Group International Limited (NASDAQ:EEIQ) shares surged 88.4% to $2.75 after gaining 8% on Tuesday. EpicQuest Education's Davis College signed a non-binding Memorandum of Understanding with Chongqing College of Electronic Engineering.
    • Enveric Biosciences, Inc. (NASDAQ:ENVB) jumped 85% to $5.83 after the company announced it received a Notice of Allowance from the USPTO for a patent application involving its EVM201 Series.
    • GigaCloud Technology Inc. (NASDAQ:GCT) shares climbed 62.2% to $9.31 after the company reported a year-over-year increase in first-quarter financial results.
    • Zura Bio Limited (NASDAQ:ZURA) shares gained 36% to $7.28 after Raymond James initiated coverage on the stock with a Strong Buy rating and a $20 price target.
    • Apexigen, Inc. (NASDAQ:APGN) gained 31% to $0.5235 after Pyxis Oncology announced it will acquire the company.
    • BiomX Inc. (NYSE:PHGE) climbed 27% to $0.3585. BiomX recently posted a narrower quarterly loss.
    • Abercrombie & Fitch Co. (NYSE:ANF) climbed 22.3% to $28.14 after the company reported better-than-expected Q1 sales results, raised FY23 net sales growth guidance and raised operating margin guidance.
    • Kingstone Companies, Inc. (NASDAQ:KINS) gained 15.7% to $1.54.
    • The Necessity Retail REIT, Inc. (NASDAQ:RTL) rose 15.2% to $5.62. Global Net Lease is scheduled to host a webcast and conference call on May 24, 2023 to discuss its merger with The Necessity Retail REIT, Inc.
    • Organogenesis Holdings Inc. (NASDAQ:ORGO) gained 14.5% to $3.94 after BTIG upgraded the stock from Neutral to Buy and announced a $10 price target.
    • Urban Outfitters, Inc. (NASDAQ:URBN) shares climbed 14.1% to $30.42 as the company reported better-than-expected results for its first quarter said inventory fell 6.3% year-over-year.
    • Kamada Ltd. (NASDAQ:KMDA) gained 13.7% to $5.32 after the company reported better-than-expected EPS results and announced a $60 million private placement with FIMI Opportunity Funds.
    • OptimizeRx Corporation (NASDAQ:OPRX) climbed 11.7% to $13.50.
    • Unique Fabricating, Inc. (NASDAQ:UFAB) gained 11.3% to $0.2670. Unique Fabricating shares gained around 23% on Tuesday after the company announced an accommodation agreement and new forbearance agreement to support a restructuring or sale.
    • Photronics, Inc. (NASDAQ:PLAB) rose 11.3% to $19.15 following better-than-expected second-quarter results.
    • Smart for Life, Inc. (NASDAQ:SMFL) shares gained 10.7% to $2.2701. Smart for Life launched a new line of Sports Illustrated protein bars specifically formulated for active lifestyles.
    • Virios Therapeutics, Inc. (NASDAQ:VIRI) gained 10.6% to $1.36.
    • Greenland Technologies Holding Corporation (NASDAQ:GTEC) jumped 10.3% to $1.70. Greenland Technologies Form4 filing showed CEO Raymond Z Wang bought 66,500 shares of stock at a common price of $1.50 per share.
    • Kohl's Corporation (NYSE:KSS) climbed 8.5% to $20.91 after the company reported better-than-expected Q1 total revenue results and reaffirmed FY23 outlook.
    • Ambow Education Holding Ltd. (NYSE:AMBO) gained 8.4% to $0.2495.
    • Palo Alto Networks, Inc. (NASDAQ:PANW) surged 8% to $204.90 after the company reported better-than-expected Q3 results and issued strong guidance.
    • Invivyd, Inc. (NASDAQ:IVVD) gained 6.5% to $1.81.

    Losers

    • BIOLASE, Inc. (NASDAQ:BIOL) fell 42% to $0.0813 after the company announced the pricing of a $4.5 million underwritten public offering.
    • QualTek Services Inc. (NASDAQ:QTEK) dropped 38.4% to $0.1083 after the company filed voluntarily petitions for Chapter 11 bankruptcy.
    • Ocugen, Inc. (NASDAQ:OCGN) fell 36.4% to $0.4570 after the company reported pricing of $16.5 million public offering of common stock.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) dropped 28.7% to $0.1390. Biodexa Pharmaceuticals announced $3.32 million registered direct offering of 22,135,922 new American Depositary Shares at a price of $0.15 per ADS.
    • CohBar, Inc. (NASDAQ:CWBR) shares fell 27.2% to $3.6478. CohBar shares jumped 223% on Tuesday after the company and Morphogenesis announced they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) fell 25.2% to $0.13.
    • The Children's Place, Inc. (NASDAQ:PLCE) dropped 24.7% to $17.87 after the company reported worse-than-expected Q1 financial results and issued FY23 adjusted EPS and revenue guidance below estimates.
    • Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) fell 23% to $7.84 after the company posted first-quarter results.
    • PTC Therapeutics, Inc. (NASDAQ:PTCT) fell 22.5% to $45.19 after the company announced its MOVE-FA trial of vatiquinone did not meet its primary endpoint. The company will discontinue its preclinical and early research gene therapy programs.
    • Navitas Semiconductor Corporation (NASDAQ:NVTS) dipped 22% to $7.31. Navitas Semiconductor priced 10 million share common stock offering at $8 per share.
    • HeartCore Enterprises, Inc. (NASDAQ:HTCR) fell 20.3% to $1.9602. Heartcore Enterprises shares jumped 92% on Tuesday after the company reported better-than-expected first-quarter EPS and sales results.
    • The NFT Gaming Company, Inc. (NASDAQ:NFTG) dropped 20% to $0.80.
    • Ocean Biomedical, Inc. (NASDAQ:OCEA) fell 18.5% to $5.49. Ocean Biomedical recently announced a patent award for novel cancer immunotherapy treatment, granted for prostate cancer, colon cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma and lung cancer.
    • Express, Inc. (NYSE:EXPR) dropped 16.6% to $0.6781 after the company reported worse-than-expected Q1 sales results and issued Q2 sales guidance with a midpoint below estimates.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) declined 15.7% to $1.8201 after the company announced a $1.8 million offering of 800,877 shares of its common stock at a price of $2.285 per share.
    • Hesai Group (NASDAQ:HSAI) dropped 14.7% to $7.99 following quarterly results.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) fell 13.1% to $3.31. Mizuho maintained WAVE Life Sciences with a Buy and lowered the price target from $13 to $10.
    • SeqLL Inc. (NASDAQ:SQL) fell 13% to $0.4880 after jumping 40% on Tuesday. The company recently posted a wider quarterly loss.
    • Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) dropped 13% to $0.1044. Navidea Biopharmaceuticals announced the sale of preferred shares totaling $1.1 million to new existing investors.
    • Global Net Lease, Inc. (NYSE:GNL) fell 12.5% to $9.24 after the company and The Necessity Retail REIT announced a merger agreement.
    • America's Car-Mart, Inc. (NASDAQ:CRMT) dropped 11.8% to $78.73 following weak quarterly earnings.
    • Sarepta Therapeutics, Inc. (NASDAQ:SRPT) fell 11.3% to $130.34 after the company announced an update on the regulatory review of SRP-9001.
    • XPeng Inc. (NYSE:XPEV) fell 11.3% to $8.08 after the company reported worse-than-expected Q1 financial results, issued Q2 revenue guidance below estimates and said it sees a year-over-year decrease in Q2 vehicle deliveries.
    • Tingo Group, Inc. (NASDAQ:TIO) dropped 11% to $4.2492.
    • NIO Inc. (NYSE:NIO) fell 10.6% to $7.82.
    • D-Wave Quantum Inc. (NYSE:QBTS) fell 10.4% to $0.9052. D-Wave Quantum recently hosted two government officials at its Burnaby offices to highlight the company's innovation in quantum computing.
    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) dropped 9.9% to $4.4399.
    • Hyliion Holdings Corp. (NYSE:HYLN) fell 9.5% to $1.6552.
    • Agilent Technologies, Inc. (NYSE:A) shares fell 9.1% to $116.96 after the company cut its FY23 revenue outlook.
    • U.S. Physical Therapy, Inc. (NYSE:USPH) dropped 9% to $99.49. U.S. Physical Therapy announced $150 million underwritten public offering of common stock.
    • Analog Devices, Inc. (NASDAQ:ADI) fell 8.4% to $172.05 following Q2 results.
    • T Stamp Inc. (NASDAQ:IDAI) shares dropped 8% to $1.73. T Stamp shares jumped around 30% on Tuesday after the company announced it has received a Notice of Allowance for an additional patent by the United States Patent and Trademark Office related to its AI-powered, tokenized-identity products.

     

    Now Read This: Dow Falls Over 100 Points; Analog Devices Posts Upbeat Q2 Earnings

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $ADI
    $AMBO
    $ANF

    CompanyDatePrice TargetRatingAnalyst
    Analog Devices Inc.
    $ADI
    3/30/2026$389.00Neutral → Buy
    Arete
    Hesai Group
    $HSAI
    3/26/2026Outperform
    BNP Paribas Exane
    Abercrombie & Fitch Company
    $ANF
    3/26/2026$108.00Buy
    Needham
    XPeng Inc.
    $XPEV
    3/23/2026$19.00Outperform → Neutral
    Macquarie
    Photronics Inc.
    $PLAB
    3/20/2026$46.00Buy
    Lake Street
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    Petco Health and Wellness Company Inc.
    $WOOF
    3/12/2026$5.00Hold → Buy
    Jefferies
    More analyst ratings

    $A
    $ADI
    $AMBO
    $ANF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 5:45:41 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ADI
    $AMBO
    $ANF
    SEC Filings

    View All

    SEC Form PRE 14A filed by Enveric Biosciences Inc.

    PRE 14A - Enveric Biosciences, Inc. (0000890821) (Filer)

    4/3/26 5:05:48 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    4/3/26 4:05:10 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Greenland Technologies Holding Corporation

    EFFECT - Greenland Technologies Holding Corp. (0001735041) (Filer)

    4/3/26 12:15:29 AM ET
    $GTEC
    Industrial Machinery/Components
    Industrials

    $A
    $ADI
    $AMBO
    $ANF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ADI
    $AMBO
    $ANF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analog Devices upgraded by Arete with a new price target

    Arete upgraded Analog Devices from Neutral to Buy and set a new price target of $389.00

    3/30/26 8:10:39 AM ET
    $ADI
    Semiconductors
    Technology

    BNP Paribas Exane initiated coverage on Hesai Group

    BNP Paribas Exane initiated coverage of Hesai Group with a rating of Outperform

    3/26/26 8:49:19 AM ET
    $HSAI
    Industrial Machinery/Components
    Industrials

    Needham initiated coverage on Abercrombie & Fitch with a new price target

    Needham initiated coverage of Abercrombie & Fitch with a rating of Buy and set a new price target of $108.00

    3/26/26 8:44:16 AM ET
    $ANF
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $A
    $ADI
    $AMBO
    $ANF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tyson Mitchell G

    4 - PHOTRONICS INC (0000810136) (Issuer)

    4/3/26 7:39:59 PM ET
    $PLAB
    Semiconductors
    Technology

    SEC Form 4 filed by Wang Hsueh-Chun

    4 - PHOTRONICS INC (0000810136) (Issuer)

    4/3/26 7:34:46 PM ET
    $PLAB
    Semiconductors
    Technology

    SEC Form 4 filed by Timm Jill

    4 - KOHLS Corp (0000885639) (Issuer)

    4/3/26 5:35:05 PM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    $A
    $ADI
    $AMBO
    $ANF
    Leadership Updates

    Live Leadership Updates

    View All

    Global Net Lease, Inc. Announces Retirement of Two Board Members

    NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. ("GNL" or the "Company") today announced that Sue Perrotty and Governor Edward Rendell have decided to retire from the Company's Board of Directors (the "Board") effective immediately following the 2026 Annual Meeting of Stockholders and will not stand for re-election at the Annual Meeting. "On behalf of the Board, I want to thank Sue and Governor Rendell for their contributions to GNL during their 11 and 14 years of dedicated service, respectively, particularly their leadership guiding the Company through the merger and internalization in 2023. We wish them both the very best in the future," said Rob Kauffman, Non-Execut

    4/2/26 6:00:00 AM ET
    $GNL
    Real Estate Investment Trusts
    Real Estate

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $ADI
    $AMBO
    $ANF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    $A
    $ADI
    $AMBO
    $ANF
    Financials

    Live finance-specific insights

    View All

    Cheche Group Reports Second Half and Full Year 2025 Unaudited Financial Results

    BEIJING, April 2, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche," "the Company" or "we"), China's leading auto insurance technology platform, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Key Business HighlightsPartnerships with New Energy Vehicle (NEV) companies(1) reached 16 in the second half 2025 and led to 1.2 million policies with corresponding written premium of RMB3.7 billion (US$532.0 million), representing an increase of 61.8% and 63.9%, respectively, compared to the prior-year period. Embedded policies and corresponding written premium for the full year 2025 reached 2.0 million and RMB6.3 billion (US$902.1

    4/2/26 6:00:00 AM ET
    $CCG
    $NIO
    Specialty Insurers
    Finance
    Auto Manufacturing
    Industrials

    Kingstone CEO Meryl Golden Issues Shareholder Letter Following Record 2025 Results, Outlines Measured Expansion into California

    KINGSTON, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Kingstone Companies, Inc. (NASDAQ:KINS) ("Kingstone" or the "Company"), a Northeast regional property and casualty insurance holding company, today released the following letter to shareholders from President and Chief Executive Officer Meryl Golden regarding the Company's entry into the California excess and surplus lines homeowners market. Dear Fellow Shareholders, Four years ago, Kingstone was an underperforming business. We were overexposed in states where we had no competitive advantage, selling a product that did not match rate to risk and running at a 41% net expense ratio. We made a series of difficult but necessary decisions—red

    4/1/26 4:15:00 PM ET
    $KINS
    Property-Casualty Insurers
    Finance

    Global Net Lease, Inc. Announces Common Stock Dividend for the Second Quarter 2026

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. ("GNL" or the "Company") (NYSE:GNL) announced today that it declared a dividend of $0.190 per share of common stock payable on April 17, 2026, to common stockholders of record at the close of business on April 13, 2026. Dividends authorized by the Company's board of directors and declared by the Company are paid on a quarterly basis in arrears during the first month following the end of each fiscal quarter (unless otherwise specified) to common stockholders of record on the record date for such payment. About Global Net Lease, Inc.Global Net Lease, Inc. (NYSE:GNL) is a publicly traded internally managed real estate inves

    4/1/26 6:00:00 AM ET
    $GNL
    Real Estate Investment Trusts
    Real Estate

    $A
    $ADI
    $AMBO
    $ANF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

    April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s

    4/2/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cheche Group Reports Second Half and Full Year 2025 Unaudited Financial Results

    BEIJING, April 2, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche," "the Company" or "we"), China's leading auto insurance technology platform, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Key Business HighlightsPartnerships with New Energy Vehicle (NEV) companies(1) reached 16 in the second half 2025 and led to 1.2 million policies with corresponding written premium of RMB3.7 billion (US$532.0 million), representing an increase of 61.8% and 63.9%, respectively, compared to the prior-year period. Embedded policies and corresponding written premium for the full year 2025 reached 2.0 million and RMB6.3 billion (US$902.1

    4/2/26 6:00:00 AM ET
    $CCG
    $NIO
    Specialty Insurers
    Finance
    Auto Manufacturing
    Industrials

    Global Net Lease, Inc. Announces Retirement of Two Board Members

    NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. ("GNL" or the "Company") today announced that Sue Perrotty and Governor Edward Rendell have decided to retire from the Company's Board of Directors (the "Board") effective immediately following the 2026 Annual Meeting of Stockholders and will not stand for re-election at the Annual Meeting. "On behalf of the Board, I want to thank Sue and Governor Rendell for their contributions to GNL during their 11 and 14 years of dedicated service, respectively, particularly their leadership guiding the Company through the merger and internalization in 2023. We wish them both the very best in the future," said Rob Kauffman, Non-Execut

    4/2/26 6:00:00 AM ET
    $GNL
    Real Estate Investment Trusts
    Real Estate